Table 1.
Patients’ and treatment characteristics according to the time-gap to CRT.
| Variant | Total, n (%) |
<28 d (%) |
35–42 d (%) |
> 42 d (%) |
p - value |
|---|---|---|---|---|---|
| Age at diagnosis, n | 204 | 47 | 72 | 84 | 0.39 |
| <40 y | 11 (5.4) | 3 (6.4) | 5 (7) | 3 (4) | |
| 40–64 y | 126 (61.7) | 24 (51) | 46 (64) | 56 (64 | |
| >64 y |
67 (32.8) |
20 (42.6) | 21 (29) | 25 (32) | |
| Gender, n | 204 | 47 | 72 | 84 | 0.5 |
| Male |
126 (61.7) |
28 (59.6) | 42 (59) | 56 (67) | |
| Female |
78 (38) |
19 (40. 4) | 30 (41) | 28 (33) | |
| Extent of surgical resection, n | 202 | 45 | 72 | 46 | 0.059 |
| Gross total resection |
128 (63) |
21 (46) | 46 (64) | 23 (50) | |
| Subtotal resection |
28 (13.9) |
8 (18) | 9 (12) | 10 (21) | |
| Biopsy |
46 (22.7) |
16 (36) | 17 (24) | 13 (29) | |
| MGMT status, n | 38 | 11 | 7 | 20 | 0.17 |
| Positive |
16 (42) |
4 (36) | 1 (14) | 11 (55) | |
| Negative |
22 (57.9) |
7 (64) | 6 (86) | 9 (45) | |
| Comorbidities at diagnosis, n | 147 | 39 | 52 | 55 | |
| Diabetes Mellitus |
44 (29.9) |
11 (28) | 16 (31) | 17 (31) | 0.9 |
| Hypertension |
93 (63) |
24 (62) | 32 (62) | 36 (65) | 0.65 |
| Ischemic heart disease |
10 (6.8) |
4 (10) | 4 (7) | 2 (4) | 0.28 |
| RT total dose (Gy), n | 188 | 40 | 67 | 80 | 0.047 |
| ≥56 |
166 (88.3) |
31(77.5) | 60 (90) | 74 (93) | |
| 36–50 |
17 (9) |
7 (17.5) | 4 (6) | 6 (7) | |
| ≤32 |
5 (2.6) |
2 (5) | 3 (4) | 0 (0) | |
| No. of adjuvant TMZ cycles*, n | 200 | 45 | 70 | 84 | 0.88 |
| 0 |
18 (9) |
4 (9) | 6 (9) | 8 (10) | |
| 1–3 |
80 (40) |
22 (48) | 23 (33) | 35 (42) | |
| 4–6 |
47 (23.5) |
8 (18) | 19 (27) | 20 (24) | |
| 7–9 |
19 (9.5) |
4 (9) | 8 (11) | 7 (8) | |
| ≥10 |
36 (18) |
7 (16) | 14 (20) | 14 (16) | |
| No. of Patients who switched to 2nd line therapy | 204 | 47 | 72 | 84 | 0.2 |
| Yes |
114 (56) |
21 (45) | 41 (57) | 51 (61) | |
| No |
90 (44) |
26 (55) | 31 (43) | 33 (39) | |
| Pauses during RT | 188 | 38 | 69 | 80 | 0.4 |
| Yes |
21 (11) |
2 (5) | 4 (6) | 14 (18) | |
| No |
167 (89) |
36 (95) | 65 (94) | 66 (82) | |
| Steroid use during RT | 201 | 46 | 71 | 83 | 0.29 |
| Yes |
181 (90) |
40 (87) | 67 (94) | 73 (88) | |
| No |
20 (10) |
6 (13) | 4 (6) | 10 (12) | |
| *Post concomitant therapy with RT + TMZ. | |||||
CRT- chemoradiation; RT- radiation therapy; TMZ-tomozolamide; MGMT – methylguaninemethyltransferase.
P < 0.05 is statistically significant.